The group's principal activities are to discover and develop proprietary pharmaceuticals for the treatment of inflammatory diseases and other serious medical conditions. the group combines capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression to develop highly innovative products with significant commercial potential. the group and its collaboration partners have the following product candidates in development: cialis (tm), pafase (r), tbc3711, ic14, ic747, ic485 and rtx (tm).